278 related articles for article (PubMed ID: 12435109)
1. Overcoming multidrug resistance in taxane chemotherapy.
Geney R; Ungureanu lM; Li D; Ojima I
Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry and chemical biology of new generation taxane antitumor agents.
Ojima I; Geney R; Ungureanu IM; Li D
IUBMB Life; 2002; 53(4-5):269-74. PubMed ID: 12121008
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
4. Chemistry and chemical biology of taxane anticancer agents.
Miller ML; Ojima I
Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127.
Ferlini C; Distefano M; Pierelli L; Bonanno G; Riva A; Bombardelli E; Ojima I; Mancuso S; Scambia G
Oncol Res; 1999; 11(10):471-8. PubMed ID: 10850888
[TBL] [Abstract][Full Text] [Related]
6. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
[TBL] [Abstract][Full Text] [Related]
9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
10. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Brooks TA; Minderman H; O'Loughlin KL; Pera P; Ojima I; Baer MR; Bernacki RJ
Mol Cancer Ther; 2003 Nov; 2(11):1195-205. PubMed ID: 14617793
[TBL] [Abstract][Full Text] [Related]
11. IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Nicoletti MI; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati MB; Bombardelli E; D'Incalci M; Giavazzi R
Cancer Res; 2000 Feb; 60(4):842-6. PubMed ID: 10706091
[TBL] [Abstract][Full Text] [Related]
12. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
[TBL] [Abstract][Full Text] [Related]
14. [New taxanes and epothilone derivatives in clinical trials].
Lavelle F
Bull Cancer; 2002 Apr; 89(4):343-50. PubMed ID: 12016034
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
16. Development of taxane resistance in a panel of human lung cancer cell lines.
Breen L; Murphy L; Keenan J; Clynes M
Toxicol In Vitro; 2008 Aug; 22(5):1234-41. PubMed ID: 18514476
[TBL] [Abstract][Full Text] [Related]
17. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
18. [Search for new MDR modifier possessing taxane skeleton].
Kobayashi J
Nihon Rinsho; 1997 May; 55(5):1135-42. PubMed ID: 9155165
[TBL] [Abstract][Full Text] [Related]
19. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Ehrlichova M; Vaclavikova R; Ojima I; Pepe A; Kuznetsova LV; Chen J; Truksa J; Kovar J; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):95-105. PubMed ID: 16059735
[TBL] [Abstract][Full Text] [Related]
20. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]